229 related articles for article (PubMed ID: 17115689)
1. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis.
Argyrou A; Jin L; Siconilfi-Baez L; Angeletti RH; Blanchard JS
Biochemistry; 2006 Nov; 45(47):13947-53. PubMed ID: 17115689
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
3. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
4. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
5. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.
Nguyen M; Quémard A; Broussy S; Bernadou J; Meunier B
Antimicrob Agents Chemother; 2002 Jul; 46(7):2137-44. PubMed ID: 12069966
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
Wang F; Jain P; Gulten G; Liu Z; Feng Y; Ganesula K; Motiwala AS; Ioerger TR; Alland D; Vilchèze C; Jacobs WR; Sacchettini JC
Antimicrob Agents Chemother; 2010 Sep; 54(9):3776-82. PubMed ID: 20566771
[TBL] [Abstract][Full Text] [Related]
7. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
8. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
9. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
10. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
11. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
12. Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis.
Campanerut-Sá PA; Ghiraldi-Lopes LD; Meneguello JE; Fiorini A; Evaristo GP; Siqueira VL; Scodro RB; Patussi EV; Donatti L; Souza EM; Cardoso RF
Future Microbiol; 2016 Sep; 11():1123-32. PubMed ID: 27545345
[TBL] [Abstract][Full Text] [Related]
13. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
14. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.
Raghunandanan S; Jose L; Kumar RA
J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901
[TBL] [Abstract][Full Text] [Related]
15. Computational approach identifies protein off-targets for Isoniazid-NAD adduct: hypothesizing a possible drug resistance mechanism in
Hassan S; Sudhakar V; Nancy Mary MB; Babu R; Doble M; Dadar M; Hanna LE
J Biomol Struct Dyn; 2020 Apr; 38(6):1697-1710. PubMed ID: 31094664
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against
Zhu C; Liu Y; Hu L; Yang M; He ZG
J Biol Chem; 2018 Oct; 293(43):16741-16750. PubMed ID: 30185616
[TBL] [Abstract][Full Text] [Related]
17. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach.
Chollet A; Mourey L; Lherbet C; Delbot A; Julien S; Baltas M; Bernadou J; Pratviel G; Maveyraud L; Bernardes-Génisson V
J Struct Biol; 2015 Jun; 190(3):328-37. PubMed ID: 25891098
[TBL] [Abstract][Full Text] [Related]
19. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria.
Vilchèze C; Weisbrod TR; Chen B; Kremer L; Hazbón MH; Wang F; Alland D; Sacchettini JC; Jacobs WR
Antimicrob Agents Chemother; 2005 Feb; 49(2):708-20. PubMed ID: 15673755
[TBL] [Abstract][Full Text] [Related]
20. The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.
Tseng ST; Tai CH; Li CR; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2015 Jun; 48(3):249-55. PubMed ID: 24184004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
